Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
Purpose To evaluate the efficacy of intravitreal aflibercept monotherapy for submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). Methods This prospective, phase 4 clinical trial included 29 patients diagnosed with fovea-i...
Gespeichert in:
| Veröffentlicht in: | Graefe's archive for clinical and experimental ophthalmology 2020, Vol.258 (1), p.107-116 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 116 |
|---|---|
| container_issue | 1 |
| container_start_page | 107 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 258 |
| creator | Kim, Jae Hui Kim, Chul Gu Lee, Dong Won Yoo, Su Jin Lew, Young Ju Cho, Han Joo Kim, Joo Yeon Lee, Seok Hyun Kim, Jong Woo |
| description | Purpose
To evaluate the efficacy of intravitreal aflibercept monotherapy for submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
Methods
This prospective, phase 4 clinical trial included 29 patients diagnosed with fovea-involving submacular hemorrhage secondary to neovascular AMD (7 patients) or PCV (22 patients). Patients were initially administered 3 monthly aflibercept injections, followed by 1 injection every 2 months. The primary outcome measure was changes in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) during the 56-week study period. Other key outcome measures were the proportion of patients who exhibited changes in BCVA of ≥ 15 ETDRS letters from baseline and changes in central retinal thickness (CRT).
Results
The mean size of hemorrhage was 6.2 ± 4.8-disc-diameter area. The mean BCVA significantly improved from 52.9 ± 17.8 ETDRS letters at week 0 (baseline) to 71.8 ± 16.1 letters at week 56 (
P
|
| doi_str_mv | 10.1007/s00417-019-04474-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2331783761</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2315970320</sourcerecordid><originalsourceid>FETCH-LOGICAL-p213t-ecdb6388a885033eefba8830f77918b0fcdb6e65056a14b355865fcf74a7439b3</originalsourceid><addsrcrecordid>eNpdkc1O3DAUhS1UBMPPC3RRWeqmG5fr2I4zywpRQEJiAxI76ya5mQnKxKntIM1r9IlrCAipK1_pfPfYPoexrxJ-SgB7EQG0tALkWoDWVgs4YCuplREWiqcvbAW2kKJSxdMxO4nxGTKvjDxix0paLfPOiv29HVPAlz4FwoFjN_Q1hYamxDsfeJzrHTbzgIFvaedD2OKGeKTGjy2GPU-ej-RfMC5MFkWgARO1_GOvpQ2NFDD1fuQ4tnzyw37yfZuva7Y-LNNi4SdM2_0ZO-xwiHT-fp6yx99XD5c34u7--vby152YCqmSoKatS1VVWFUGlCLq6jwq6Kxdy6qG7lWn0oApUepaGVOVpms6q9Fqta7VKfux-E7B_5kpJrfrY0PDgPlPc3SFkmZtQRWQ0e__oc9-DmN-XaZymJWypczUt3cqx0atm0K_yym5j7QzoBYgZmncUPi0keBeO3VLpy536t46daD-AfU7laY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2331783761</pqid></control><display><type>article</type><title>Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy</title><source>SpringerLink Journals - AutoHoldings</source><creator>Kim, Jae Hui ; Kim, Chul Gu ; Lee, Dong Won ; Yoo, Su Jin ; Lew, Young Ju ; Cho, Han Joo ; Kim, Joo Yeon ; Lee, Seok Hyun ; Kim, Jong Woo</creator><creatorcontrib>Kim, Jae Hui ; Kim, Chul Gu ; Lee, Dong Won ; Yoo, Su Jin ; Lew, Young Ju ; Cho, Han Joo ; Kim, Joo Yeon ; Lee, Seok Hyun ; Kim, Jong Woo</creatorcontrib><description>Purpose
To evaluate the efficacy of intravitreal aflibercept monotherapy for submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
Methods
This prospective, phase 4 clinical trial included 29 patients diagnosed with fovea-involving submacular hemorrhage secondary to neovascular AMD (7 patients) or PCV (22 patients). Patients were initially administered 3 monthly aflibercept injections, followed by 1 injection every 2 months. The primary outcome measure was changes in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) during the 56-week study period. Other key outcome measures were the proportion of patients who exhibited changes in BCVA of ≥ 15 ETDRS letters from baseline and changes in central retinal thickness (CRT).
Results
The mean size of hemorrhage was 6.2 ± 4.8-disc-diameter area. The mean BCVA significantly improved from 52.9 ± 17.8 ETDRS letters at week 0 (baseline) to 71.8 ± 16.1 letters at week 56 (
P
< 0.001). At week 56, improvement in BCVA of ≥ 15 letters was noted in 16 patients (55.2%), whereas none of the patients experienced a loss of ≥ 15 letters. The mean CRT significantly decreased from 498.9 ± 194.2 μm at week 0 to 248.3 ± 45.0 μm at week 56 (
P
< 0.001). During the study period, retinal break developed in one patient.
Conclusions
Intravitreal aflibercept administered every 2 months after the 3 initial monthly doses was found to be an effective and safe treatment method for submacular hemorrhage secondary to neovascular AMD.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-019-04474-0</identifier><identifier>PMID: 31741044</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Acuity ; Age ; Diabetes mellitus ; Diabetic retinopathy ; Eye ; Hemorrhage ; Macular degeneration ; Medicine ; Medicine & Public Health ; Ophthalmology ; Patients ; Retina ; Retinal Disorders ; Retinopathy ; Vascular diseases</subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2020, Vol.258 (1), p.107-116</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>Graefe's Archive for Clinical and Experimental Ophthalmology is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-p213t-ecdb6388a885033eefba8830f77918b0fcdb6e65056a14b355865fcf74a7439b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00417-019-04474-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00417-019-04474-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31741044$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Jae Hui</creatorcontrib><creatorcontrib>Kim, Chul Gu</creatorcontrib><creatorcontrib>Lee, Dong Won</creatorcontrib><creatorcontrib>Yoo, Su Jin</creatorcontrib><creatorcontrib>Lew, Young Ju</creatorcontrib><creatorcontrib>Cho, Han Joo</creatorcontrib><creatorcontrib>Kim, Joo Yeon</creatorcontrib><creatorcontrib>Lee, Seok Hyun</creatorcontrib><creatorcontrib>Kim, Jong Woo</creatorcontrib><title>Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>Purpose
To evaluate the efficacy of intravitreal aflibercept monotherapy for submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
Methods
This prospective, phase 4 clinical trial included 29 patients diagnosed with fovea-involving submacular hemorrhage secondary to neovascular AMD (7 patients) or PCV (22 patients). Patients were initially administered 3 monthly aflibercept injections, followed by 1 injection every 2 months. The primary outcome measure was changes in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) during the 56-week study period. Other key outcome measures were the proportion of patients who exhibited changes in BCVA of ≥ 15 ETDRS letters from baseline and changes in central retinal thickness (CRT).
Results
The mean size of hemorrhage was 6.2 ± 4.8-disc-diameter area. The mean BCVA significantly improved from 52.9 ± 17.8 ETDRS letters at week 0 (baseline) to 71.8 ± 16.1 letters at week 56 (
P
< 0.001). At week 56, improvement in BCVA of ≥ 15 letters was noted in 16 patients (55.2%), whereas none of the patients experienced a loss of ≥ 15 letters. The mean CRT significantly decreased from 498.9 ± 194.2 μm at week 0 to 248.3 ± 45.0 μm at week 56 (
P
< 0.001). During the study period, retinal break developed in one patient.
Conclusions
Intravitreal aflibercept administered every 2 months after the 3 initial monthly doses was found to be an effective and safe treatment method for submacular hemorrhage secondary to neovascular AMD.</description><subject>Acuity</subject><subject>Age</subject><subject>Diabetes mellitus</subject><subject>Diabetic retinopathy</subject><subject>Eye</subject><subject>Hemorrhage</subject><subject>Macular degeneration</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Retina</subject><subject>Retinal Disorders</subject><subject>Retinopathy</subject><subject>Vascular diseases</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkc1O3DAUhS1UBMPPC3RRWeqmG5fr2I4zywpRQEJiAxI76ya5mQnKxKntIM1r9IlrCAipK1_pfPfYPoexrxJ-SgB7EQG0tALkWoDWVgs4YCuplREWiqcvbAW2kKJSxdMxO4nxGTKvjDxix0paLfPOiv29HVPAlz4FwoFjN_Q1hYamxDsfeJzrHTbzgIFvaedD2OKGeKTGjy2GPU-ej-RfMC5MFkWgARO1_GOvpQ2NFDD1fuQ4tnzyw37yfZuva7Y-LNNi4SdM2_0ZO-xwiHT-fp6yx99XD5c34u7--vby152YCqmSoKatS1VVWFUGlCLq6jwq6Kxdy6qG7lWn0oApUepaGVOVpms6q9Fqta7VKfux-E7B_5kpJrfrY0PDgPlPc3SFkmZtQRWQ0e__oc9-DmN-XaZymJWypczUt3cqx0atm0K_yym5j7QzoBYgZmncUPi0keBeO3VLpy536t46daD-AfU7laY</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Kim, Jae Hui</creator><creator>Kim, Chul Gu</creator><creator>Lee, Dong Won</creator><creator>Yoo, Su Jin</creator><creator>Lew, Young Ju</creator><creator>Cho, Han Joo</creator><creator>Kim, Joo Yeon</creator><creator>Lee, Seok Hyun</creator><creator>Kim, Jong Woo</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2020</creationdate><title>Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy</title><author>Kim, Jae Hui ; Kim, Chul Gu ; Lee, Dong Won ; Yoo, Su Jin ; Lew, Young Ju ; Cho, Han Joo ; Kim, Joo Yeon ; Lee, Seok Hyun ; Kim, Jong Woo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p213t-ecdb6388a885033eefba8830f77918b0fcdb6e65056a14b355865fcf74a7439b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acuity</topic><topic>Age</topic><topic>Diabetes mellitus</topic><topic>Diabetic retinopathy</topic><topic>Eye</topic><topic>Hemorrhage</topic><topic>Macular degeneration</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Retina</topic><topic>Retinal Disorders</topic><topic>Retinopathy</topic><topic>Vascular diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Jae Hui</creatorcontrib><creatorcontrib>Kim, Chul Gu</creatorcontrib><creatorcontrib>Lee, Dong Won</creatorcontrib><creatorcontrib>Yoo, Su Jin</creatorcontrib><creatorcontrib>Lew, Young Ju</creatorcontrib><creatorcontrib>Cho, Han Joo</creatorcontrib><creatorcontrib>Kim, Joo Yeon</creatorcontrib><creatorcontrib>Lee, Seok Hyun</creatorcontrib><creatorcontrib>Kim, Jong Woo</creatorcontrib><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Jae Hui</au><au>Kim, Chul Gu</au><au>Lee, Dong Won</au><au>Yoo, Su Jin</au><au>Lew, Young Ju</au><au>Cho, Han Joo</au><au>Kim, Joo Yeon</au><au>Lee, Seok Hyun</au><au>Kim, Jong Woo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><stitle>Graefes Arch Clin Exp Ophthalmol</stitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2020</date><risdate>2020</risdate><volume>258</volume><issue>1</issue><spage>107</spage><epage>116</epage><pages>107-116</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>Purpose
To evaluate the efficacy of intravitreal aflibercept monotherapy for submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
Methods
This prospective, phase 4 clinical trial included 29 patients diagnosed with fovea-involving submacular hemorrhage secondary to neovascular AMD (7 patients) or PCV (22 patients). Patients were initially administered 3 monthly aflibercept injections, followed by 1 injection every 2 months. The primary outcome measure was changes in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) during the 56-week study period. Other key outcome measures were the proportion of patients who exhibited changes in BCVA of ≥ 15 ETDRS letters from baseline and changes in central retinal thickness (CRT).
Results
The mean size of hemorrhage was 6.2 ± 4.8-disc-diameter area. The mean BCVA significantly improved from 52.9 ± 17.8 ETDRS letters at week 0 (baseline) to 71.8 ± 16.1 letters at week 56 (
P
< 0.001). At week 56, improvement in BCVA of ≥ 15 letters was noted in 16 patients (55.2%), whereas none of the patients experienced a loss of ≥ 15 letters. The mean CRT significantly decreased from 498.9 ± 194.2 μm at week 0 to 248.3 ± 45.0 μm at week 56 (
P
< 0.001). During the study period, retinal break developed in one patient.
Conclusions
Intravitreal aflibercept administered every 2 months after the 3 initial monthly doses was found to be an effective and safe treatment method for submacular hemorrhage secondary to neovascular AMD.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>31741044</pmid><doi>10.1007/s00417-019-04474-0</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2020, Vol.258 (1), p.107-116 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_proquest_journals_2331783761 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Acuity Age Diabetes mellitus Diabetic retinopathy Eye Hemorrhage Macular degeneration Medicine Medicine & Public Health Ophthalmology Patients Retina Retinal Disorders Retinopathy Vascular diseases |
| title | Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A03%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravitreal%20aflibercept%20for%20submacular%20hemorrhage%20secondary%20to%20neovascular%20age-related%20macular%20degeneration%20and%20polypoidal%20choroidal%20vasculopathy&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Kim,%20Jae%20Hui&rft.date=2020&rft.volume=258&rft.issue=1&rft.spage=107&rft.epage=116&rft.pages=107-116&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-019-04474-0&rft_dat=%3Cproquest_pubme%3E2315970320%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2331783761&rft_id=info:pmid/31741044&rfr_iscdi=true |